Icterus neonatorum presentation for studentsNehaNupur8
Introduction
Definition
Metabolism and excretion of bilirubin
Causes
Symptoms
Types
Physiological jaundice
Pathological jaundice
Breast milk jaundice
Neo natal jaundice is a yellow discoloration of the white part of the eyes and skin in a newborn baby due to high bilirubin level.
Neo natal jaundice becomes apparent at serum bilirubin concentration of 5-7mg / dL.
Shoulder and trunk 8-10mg/dl
Lower body – 10-12mg/dl.
Entire body 12-15 mg /DL
Icterus neonatorum presentation for studentsNehaNupur8
Introduction
Definition
Metabolism and excretion of bilirubin
Causes
Symptoms
Types
Physiological jaundice
Pathological jaundice
Breast milk jaundice
Neo natal jaundice is a yellow discoloration of the white part of the eyes and skin in a newborn baby due to high bilirubin level.
Neo natal jaundice becomes apparent at serum bilirubin concentration of 5-7mg / dL.
Shoulder and trunk 8-10mg/dl
Lower body – 10-12mg/dl.
Entire body 12-15 mg /DL
Approach to neonatal jaundice - Simplified
references : Cloherty And Stark's Manual Of Neonatal Care
AIIMS Protocol In Neonatology
Care Of The Newborn – Meherban Singh
Approach to neonatal jaundice - Simplified
references : Cloherty And Stark's Manual Of Neonatal Care
AIIMS Protocol In Neonatology
Care Of The Newborn – Meherban Singh
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
3. Incidence of
neonatal
jaundice
Incidence in Term :Occurs in 60%
Preterm : 80% of preterm neonates
Jaundice is the most common
condition that requires medical
attention in newborns
Mainly unconjugated or indirect
hyperbilrubinemia is seen in
newborn
6. Types of jaundice
PATHOLOGICAL
JAUNDICE
● Appears within 24 hours of age
● Increase of bilirubin >5 mg/dl/day
● Serum bilirubin > 15 mg/dl
● Jaundice days Jaundice persisting after 14
days.
● Stool clay/white colored and urine
staining yellow staining clothes
● Direct bilirubin > 2 mg/dl
PHYSIOLOGICAL
JAUNDICE
● Appears after 24 hours
● Total bilirubin rises by less than 5 mg/dl
per day
● Maximum intensity by 4th-5th day in term
&7th day in preter
● Serum level less than 15 mg/dl Clinically
not detectable after 14 days
7. CAUSES
Of
Neonatal
jaundice
In 1st 24 Hours:
1-Hemolytic disorders (G6PD-Spherocytosis)
2-TORCH (congenital infection)
2nd day- 3rd week:
1-Physiological (disappear after the 1stweek)
2-Breast milk
3-Sepsis
4-Polycythemia
5-Cephalhematoma
6-Criggler-Najjar Syndrome
7-Hemolytic disorders
Appearance or Persistence after 3rd week:
1-Breast milk
2-Hypothyrodism
3-Pyloric stenosis
4-Cholestasis
8.
9. Breastfeeding Jaundice
● Jaundice appears between 24 and 72 hours of age, peaks by 5-15
days of life and disappears by the third week of life.
● Mild clinical jaundice in the third week of life, which may
persist into the 2nd to 3rd month of life in a few babies.
● This increased frequency of breastfeeding jaundice is due to
inadequate breastfeeding.
● Ensuring optimum breastfeeding would help decrease this kind of
jaundice.
10. Breast Milk Jaundice
● 2-4% of exclusively breastfed term babies have jaundice.( in excess of 10 mg/dL
beyond 3rd-4th weeks of life.)
● These babies should be investigated for prolonged jaundice if this is unconjugated
(not staining nappies); and other causes for prolongation have been ruled out.
● Etiology:- Pregnanediol and free fatty acids in breast milk interfere with the
conjugation,increased enterohepatic circulation
● Mothers should be advised to continue breastfeeding at frequent intervals and
TSB levels usually decline over a period of time.
● Some babies may require phototherapy.
13. Clinical Estimation
● Described by Kramer
● Dermal staining of bilirubin may be used as a clinical guide to the level of jaundice.
Dermal staining in newborn progresses in a cephalocaudal
direction. The newborn should be examined in good daylight. The
skin of forehead, chest, abdomen, thighs, legs, palms and soles
should be blanched with digital pressure and the underlying color
of skin and subcutaneous tissue should be noted.
● Yellow staining of palms and soles is a danger sign and requires urgent serum bilirubin
estimation and further management.
Non invasively,bilirubin levels can be assessed by transcutaneous bilirubinometer
14. Serum levels of total bilirubin are approximately
4-6 mg/dL (zone 1),
6-8 mg/dL (zone 2)
8-12 mg/dL (zone 3)
12-14 mg/dL (zone 4)
15 mg/dL (zone 5)
Yellow staining of palms and
soles is a DANGER SIGN
22. INVESTIGATIONS
FIRST LINE
• Total serum bilirubin
and its fractions
• Blood groups of
mother and baby
• Peripheral smear
SECOND LINE
• Hematocrit
• G6PD levels
• Sepsis screen
• TFT
• Urine for reducing substances
• Specific enzyme
24. ● Phototherapy is an effective and safe method for reducing indirect bilirubin levels,
particularly when initiated before serum bilirubin increases to levels associated with
kernicterus.
● In term infants - indirect bilirubin levels between 16 and 18 mg/dL.
● premature infants - bilirubin is at lower levels, to prevent bilirubin from reaching the
high concentrations necessitating exchange transfusion.
● Blue lights and white lights are effective
25. PRINCIPLES
1.Configurational isomerization :- Z isomers of bilirubin are converted to E
isomers.The reaction is instantaneous upon exposure to light but reversible as bilirubin
reaches the bile duct.
2.Structural Isomerization:- Irrevrsible reaction where bilirubin is converted into
lumirubin.The reaction is directly proportional to dose of phototherapy.responsible for
the main decline in TSB
26. TYPES OF PHOTOTHERAPY LIGHTS
● Compact flouroscent lamps
● Halogen bulbs
● High intensity LED
● Fibreoptic light source
With easy availability and low cost in
Inida,CFL phototherapy is being most
commonly used device.Often CFL devices
27. Side effects of phototherapy
● Increased insensible water loss
● Loose stools
● Skin rash
● Bronze baby syndrome
● Hypertherma
● May result in hypocalcemia
29. ● Exchange transfusion usually is reserved for infants with dangerously high indirect
bilirubin level who are at risk for kernicterus.
● The exchangeable level of indirect bilirubin for other infants may be estimated by
calculating 10% of birth weight in grams
30. STEPS
● Normal blood volume in neonates – 80 ml/kg in a full term baby.
● Therefore 160 ml/kg of blood is required for exchange transfusion (after blood
grouping and cross matching ).
● Procedure has to be performed under complete aseptic precautions.
● Baby placed in supine position.
● Perform Umbilical vein catheterization and confirm position by radiograph.
● If isovolumetric double exchange is to be done umbilical artery catheter is to be
inserted.
● Have the unit of blood ready.Attach the bag of blood to the tubings and confirm
orientation of 3 way stopcocks.
31. ● Establish the volume of each aliquot
● Exchange transfusion is done by the push pull technique through the umbilical
vein
● After exchange transfusion,phototherapy is continued and bilirubin lebels are
measured every 12 hours.
● Complications – metabolic acidosis, electrolyte abnormalities, hypoglycemia,
hypocalcemia, thrombocytopenia, volume overload, arrythmia, infection,
GVHD and death
32.
33. 3.Intravenous immune globulin
● IVIG in infants with Rh or ABO isoimmunization can
significantly reduce the need for exchange transfusions.
● Now IVIG has replaced exchange transfusion as the
second-line treatment in infants with isoimmune
jaundice.
● IVIG 0.5-1 gm/kg/dose IV repeat 12 hourly
34. 4.Phenobarbital (Luminal)
Hyperbilirubinemia: 3-8 mg/kg/d PO/IV initially; may
increase up to 12 mg/kg/d Not to exceed IV administration
rate of 1 mg/kg/min or 30 mg/min for infants.It increases
the hepatic glucuronly transferase activity – criggler najar
syndrome,gilbert syndrome